Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Neuronal Ceroid Lipofuscinoses Clinical Presentation

  • Author: Celia H Chang, MD; Chief Editor: Amy Kao, MD  more...
 
Updated: Dec 14, 2015
 

History and Physical Examination

CLN1 NCL (also called Santavuori-Haltia type or infantile NCL)

The infantile phenotype includes the following characteristics:

  • Retarded head growth
  • Hypotonia
  • Hyperexcitability
  • Cognitive dysfunction
  • Visual failure
  • Ataxia
  • Extrapyramidal movements
  • Spasticity
  • Myoclonus
  • Increased risk of hypothermia and bradycardia with anesthesia. [13]
  • Loss of light perception at age 2 years
  • Loss of motor and social skills at age 3 years
  • Death between ages 6 and 13 years

The late-infantile phenotype includes the following characteristics:

  • Cognitive decline, epilepsy, visual loss at age 1.5-3.5 years
  • Resembles CLN2 NCL
  • Death between ages 10 and 13 years

The juvenile phenotype includes the following characteristics:

  • Visual loss or learning disabilities at age 5-7 years
  • Resembles CLN3 NCL, except that epilepsy occurs later and motor disability occurs earlier

The adult phenotype includes the following characteristics:

  • Starts in the third decade
  • Psychiatric symptoms with progressive cognitive decline
  • Ataxia
  • Parkinsonism
  • Optic nerve atrophy
  • Alive in mid-50s

CLN2 NCL (also called Jansky-Bielschowsky type or late-infantile NCL)

The late-infantile phenotype includes the following characteristics:

  • Onset between ages 2 and 4 years
  • Epilepsy
  • Cognitive decline
  • Ataxia
  • Myoclonus
  • Extrapyramidal symptoms
  • Pyramidal symptoms
  • Blindness at age 4-6 years
  • Death before or in the second decade of life

The juvenile phenotype includes the following characteristics:

  • Onset between ages 6 and 8 years
  • Progressive cognitive decline
  • Seizures
  • Ataxia
  • Motor dysfunction
  • Variable vision loss
  • Survival up to the fourth decade possible

CLN3 NCL (also called Spielmeyer-Sjögren type, Spielmeyer-Sjögren-Vogt type, juvenile NCL, or Batten disease)

The classic phenotype includes the following characteristics.

  • Progressive visual loss at age 4-7 years, with blindness within 2-10 years
  • Speech disturbance
  • Cognitive decline, including attention problems
  • Epilepsy
  • Psychiatric symptoms in 74% of patients, including aggression
  • Parkinsonism
  • Myoclonus
  • Sleep disturbance
  • Pyramidal symptoms
  • Cerebellar symptoms
  • Extrapyramidal symptoms
  • Progressive cardiac disease with conduction abnormalities and hypertrophy [14]

In the protracted form of CLN3 NCL, only visual loss occurs until age 40 years, after which other symptoms manifest.

Neuropsychological testing

Adams et al found that children with CLN3 NCL had significant impairment in auditory attention, memory, verbal intellectual function, and fluency. Neuropsychological impairment was progressive over time and correlated with disease duration and motor function.[15, 16]

CLN4 NCL (also called Kufs disease or adult NCL)

Symptoms usually at age 30 years but can present at age 11 years. The type A form includes the following characteristics:

  • Progressive myoclonic epilepsy
  • Dementia
  • Ataxia
  • Pyramidal symptoms
  • Extrapyramidal symptoms

The type B form of CLN4 NCL includes the following characteristics:

  • Behavioral abnormalities
  • Dementia
  • Motor dysfunction
  • Ataxia
  • Extrapyramidal symptoms
  • Suprabulbar symptoms
  • Onset possibly after age 50 years

CLN5 NCL (also called Finnish variant late-infantile NCL)

See the list below:

  • Onset at age 4.5-7 years
  • Motor clumsiness
  • Concentration problems
  • Similar to CLN2 NCL, but with a slower course
  • Death in the second or third decade

CLN6 NCL (also called variant late-infantile/early juvenile NCL or Lake Cavanagh disease)

See the list below:

  • Onset between ages 18 months and 8 years
  • Visual loss
  • Seizures
  • Resembles CLN2 NCL
  • Loss of motor skills between ages 4 and 10 years
  • Death in the second or third decade

CLN7 NCL

CL7 NCL includes the following characteristics[17] :

  • Mean age of 5 years at disease onset
  • Seizures or motor impairment at onset
  • Mental regression
  • Myoclonus
  • Speech impairment
  • Loss of vision
  • Personality disorders

CLN8 NCL (also called Turkish variant late-infantile NCL or Northern epilepsy)

Turkish variant late infantile NCL includes the following characteristics:

  • Onset at age 3-7.5 years
  • Progressive visual loss
  • Speech delay
  • Seizures
  • Intellectual decline
  • Myoclonus
  • Ataxia

Northern epilepsy includes the following characteristics:

  • Epilepsy at age 5-10 years
  • Slight motor dysfunction
  • Slowly progressive mental retardation
  • May have reduced visual acuity
  • May survive to the sixth decade

CLN9 NCL

CLN9 NCL includes the following characteristics[18] :

  • Onset at age 4 years, with declining vision and seizures
  • Progressive ataxia
  • Cognitive decline
  • Rigidity
 
 
Contributor Information and Disclosures
Author

Celia H Chang, MD Health Sciences Clinical Professor, Chief, Division of Child Neurology, Department of Neurology/MIND Institute, University of California, Davis, School of Medicine

Celia H Chang, MD is a member of the following medical societies: American Academy of Neurology, Child Neurology Society

Disclosure: Nothing to disclose.

Chief Editor

Amy Kao, MD Attending Neurologist, Children's National Medical Center

Amy Kao, MD is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, Child Neurology Society

Disclosure: Have stock from Cellectar Biosciences; have stock from Varian medical systems; have stock from Express Scripts.

Acknowledgements

Beth A Pletcher, MD Associate Professor, Co-Director of The Neurofibromatosis Center of New Jersey, Department of Pediatrics, University of Medicine and Dentistry of New Jersey

Beth A Pletcher, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics, American Medical Association, and American Society of Human Genetics

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

References
  1. Mole S. UCL. NCL Resource - A gateway for Batten disease. Available at http://www.ucl.ac.uk/ncl/index.shtml.

  2. Dolisca SB, Mehta M, Pearce DA, Mink JW, Maria BL. Batten Disease: Clinical Aspects, Molecular Mechanisms, Translational Science, and Future Directions. J Child Neurol. 2013 Jul 9. [Medline].

  3. Bennett MJ, Rakheja D. The neuronal ceroid-lipofuscinoses. Dev Disabil Res Rev. 2013 Jun. 17(3):254-9. [Medline].

  4. Mink JW, Augustine EF, Adams HR, Marshall FJ, Kwon JM. Classification and natural history of the neuronal ceroid lipofuscinoses. J Child Neurol. 2013 Sep. 28 (9):1101-5. [Medline].

  5. Cialone J, Adams H, Augustine EF, et al. Females experience a more severe disease course in batten disease. J Inherit Metab Dis. 2011 Dec 14. [Medline].

  6. Persaud-Sawin DA, Mousallem T, Wang C, Zucker A, Kominami E, Boustany RM. Neuronal ceroid lipofuscinosis: a common pathway?. Pediatr Res. 2007 Feb. 61(2):146-52. [Medline].

  7. Miller JN, Pearce DA. A Novel c.776_777insA Mutation in CLN1 Leads to Infantile Neuronal Ceroid Lipofuscinosis. J Child Neurol. 2013 Jul 14. [Medline].

  8. Lyly A, von Schantz C, Salonen T, Kopra O, Saarela J, Jauhiainen M, et al. Glycosylation, transport, and complex formation of palmitoyl protein thioesterase 1 (PPT1)--distinct characteristics in neurons. BMC Cell Biol. 2007 Jun 12. 8:22. [Medline].

  9. Hobert JA, Dawson G. A novel role of the Batten disease gene CLN3: association with BMP synthesis. Biochem Biophys Res Commun. 2007 Jun 22. 358(1):111-6. [Medline].

  10. Siintola E, Topcu M, Aula N, Lohi H, Minassian BA, Paterson AD, et al. The novel neuronal ceroid lipofuscinosis gene MFSD8 encodes a putative lysosomal transporter. Am J Hum Genet. 2007 Jul. 81(1):136-46. [Medline].

  11. Schulz A, Dhar S, Rylova S. Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant. Ann Neurol. 2004 Sep. 56(3):342-50. [Medline].

  12. Schulz A, Mousallem T, Venkataramani M. The CLN9 protein, a regulator of dihydroceramide synthase. J Biol Chem. 2006 Feb 3. 281(5):2784-94. [Medline].

  13. Miao N, Levin SW, Baker EH, et al. Children with infantile neuronal ceroid lipofuscinosis have an increased risk of hypothermia and bradycardia during anesthesia. Anesth Analg. 2009 Aug. 109(2):372-8. [Medline]. [Full Text].

  14. Ostergaard JR, Rasmussen TB, Mølgaard H. Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease). Neurology. 2011 Apr 5. 76(14):1245-51. [Medline].

  15. Adams HR, Kwon J, Marshall FJ, de Blieck EA, Pearce DA, Mink JW. Neuropsychological symptoms of juvenile-onset batten disease: experiences from 2 studies. J Child Neurol. 2007 May. 22(5):621-7. [Medline].

  16. Backman ML, Santavuori PR, Aberg LE. Psychiatric symptoms of children and adolescents with juvenile neuronal ceroid lipofuscinosis. J Intellect Disabil Res. 2005 Jan. 49(Pt 1):25-32. [Medline].

  17. Online Mendelian Inheritance in Man. #610951 CEROID LIPOFUSCINOSIS, NEURONAL, 7; CLN7. Online Mendelian Inheritance in Man. Available at http://omim.org/entry/610951. Accessed: February 17, 2012.

  18. Schulz A, Dhar S, Rylova S, et al. Impaired cell adhesion and apoptosis in a novel CLN9 Batten disease variant. Ann Neurol. 2004 Sep. 56(3):342-50. [Medline].

  19. Kohan R, de Halac IN, Tapia Anzolini V. Palmitoyl Protein Thioesterase1 (PPT1) and Tripeptidyl Peptidase-I (TPP-I) are expressed in the human saliva. A reliable and non-invasive source for the diagnosis of infantile (CLN1) and late infantile (CLN2) neuronal ceroid lipofuscinoses. Clin Biochem. 2005 May. 38(5):492-4. [Medline].

  20. Chang X, Huang Y, Meng H, Jiang Y, Wu Y, Xiong H, et al. Clinical study in Chinese patients with late-infantile form neuronal ceroid lipofuscinoses. Brain Dev. 2012 Jan 13. [Medline].

  21. Worgall S, Kekatpure MV, Heier L, Ballon D, Dyke JP, Shungu D, et al. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology. 2007 Aug 7. 69(6):521-35. [Medline].

  22. Dyke JP, Voss HU, Sondhi D, Hackett NR, Worgall S, Heier LA, et al. Assessing disease severity in late infantile neuronal ceroid lipofuscinosis using quantitative MR diffusion-weighted imaging. AJNR Am J Neuroradiol. 2007 Aug. 28(7):1232-6. [Medline].

  23. Autti T, Hämäläinen J, Aberg L, Lauronen L, Tyynelä J, Van Leemput K. Thalami and corona radiata in juvenile NCL (CLN3): a voxel-based morphometric study. Eur J Neurol. 2007 Apr. 14(4):447-50. [Medline].

  24. Anderson GW, Smith VV, Brooke I, Malone M, Sebire NJ. Diagnosis of neuronal ceroid lipofuscinosis (Batten disease) by electron microscopy in peripheral blood specimens. Ultrastruct Pathol. 2006 Sep-Oct. 30(5):373-8. [Medline].

  25. Hawkins-Salsbury JA, Cooper JD, Sands MS. Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease). Biochim Biophys Acta. 2013 Nov. 1832(11):1906-9. [Medline].

  26. Kohan R, Cismondi IA, Oller-Ramirez AM, et al. Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses. Curr Pharm Biotechnol. 2011 Jun. 12(6):867-83. [Medline].

  27. Kinarivala N, Trippier PC. Progress in the Development of Small Molecule Therapeutics for the Treatment of Neuronal Ceroid Lipofuscinoses (NCLs). J Med Chem. 2015 Nov 24. [Medline].

  28. Selden NR, Al-Uzri A, Steiner R, Huhn SL. 126 CNS Stem Cell Transplantation for Neuronal Ceroid Lipofuscinoses: Summary of Long-term Follow-up Study Results. Neurosurgery. 2013 Aug. 60 Suppl 1:161-2. [Medline].

  29. Crystal RG, Sondhi D, Hackett NR. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther. 2004 Nov. 15(11):1131-54. [Medline].

  30. Griffey M, Macauley SL, Ogilvie JM. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol Ther. 2005 Sep. 12(3):413-21. [Medline].

  31. Hackett NR, Redmond DE, Sondhi D. Safety of Direct Administration of AAV2(CU)hCLN2, a Candidate Treatment for the Central Nervous System Manifestations of Late Infantile Neuronal Ceroid Lipofuscinosis, to the Brain of Rats and Nonhuman Primates. Hum Gene Ther. 2005 Nov 30. [Medline].

  32. Sondhi D, Peterson DA, Giannaris EL. AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Ther. 2005 Nov. 12(22):1618-32. [Medline].

  33. Fowler DJ, Anderson G, Vellodi A, Malone M, Sebire NJ. Electron microscopy of chorionic villus samples for prenatal diagnosis of lysosomal storage disorders. Ultrastruct Pathol. 2007 Jan-Feb. 31(1):15-21. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.